Highlights iX Biopharma Ltd.

Equities

42C

SG1BD9000009

Market Closed - Singapore S.E. Other stock markets 04:37:50 2024-05-15 am EDT			5-day change	1st Jan Change
0.043 ^SGD	+13.16%		0.00%	-4.44%

Mar. 12	Singaporean Shares End Marginally Higher; Biopharma's Shares Climb 2% on Introduction of New Sublingual Wafer	MT
Mar. 12	IX Biopharma Introduces New Sublingual Wafer	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IX Biopharma Introduces New Sublingual Wafer	Mar. 12	MT
IX Biopharma Ltd. Announces Development of Semaglutide Sublingual Wafer, Ixb 401, Targeting Diabetes and Obesity Markets	Mar. 11	CI
IX Biopharma Ltd. Unveils Novel NAD Wafers At the Centre for Healthy Longevity Conference 2024	Mar. 04	CI
IX Biopharma’s Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9%	Mar. 03	MT
IX Biopharma Stays in Red in Fiscal H1	Feb. 06	MT
IX Biopharma Ltd. Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 05	CI
IX Biopharma Unit Ends Wafermine Licensing Deal with Seelos Therapeutics; Shares Tumble 10%	Nov. 20	MT
IX Biopharma Unit Launches Anti Ageing Products in US	23-10-02	MT
IX Biopharma Ltd Announces its Wholly-Owned Subsidiary, Meltmed Inc, Introduces its New Suite of Fast-Dissolving Wafer Products in United States	23-09-29	CI
IX Biopharma Trims Losses in Fiscal H2; Shares Jump 17%	23-08-22	MT
IX Biopharma Ltd. Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-21	CI
IX Biopharma Limited Unveils Development of Interferon Wafer to Complement Respiratory Viral Diseases	23-08-15	CI
IX Biopharma Gets Regulatory Nod to List Over 24 Million Shares; Shares Drop 5%	23-07-18	MT
IX Biopharma Turns to Loss in July-December 2022 as Revenue Plummets 81%	23-02-10	MT
IX Biopharma Ltd. Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-10	CI
IX Biopharma Ltd Successfully Completes Phase 1 Sublingual Dexmedetomidine Clinical Study	23-02-09	CI
IX Biopharma Loss Widens in Fiscal H2 on Fair Value Adjustments, Foreign Exchange Losses	22-08-22	MT
IX Biopharma Ltd. Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-22	CI
IX Biopharma Issues Nearly 14 Million Shares Under Share Placement Exercise	22-07-21	MT
IX Biopharma Obtains Bourse's Nod to List Shares Under Share Placement	22-07-19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights iX Biopharma Ltd.

Equities

42C

SG1BD9000009

Highlights

Filters